Tags

Type your tag names separated by a space and hit enter

Efficacy of low dose atorvastatin in diabetic dyslipidaemia.
J Indian Med Assoc. 2009 Nov; 107(11):807-9.JI

Abstract

Coronary heart disease (CHD), the commonest cause of morbidity and mortality in patients with type 2 diabetes, requires multipronged approach for management, including especially treating dyslipidaemia with statins. We conducted this study to demonstrate that low dose (10 mg) atorvastatin is effective in reducing LDL cholesterol (LDL-C) to the target levels in patients from Indian subcontinent. Eighty-one subjects with type 2 diabetes mellitus and dyslipidaemia (LDL-C >100 mg/dl in those without coronary artery disease, n=77; LDL-C >70 mg/dl in those with coronary artery disease, n=4) were included. All patients were initiated on 10 mg atorvastatin daily. Serum lipid profile was repeated after 3 months. The mean body mass index among men and women were 25.0 +/- 4 and 26.7 +/- 3.6 kg/m2 respectively. Pretreatment mean HbA(1c) was 7.9 +/- 1.8 % and total cholesterol, triglycerides and HDL cholestrol (HDL-C) and LDL-C was 214 +/- 27 mg/dl, 164 +/- 63 mg/dl, 46 +/- 6 mg/dl and 135 +/- 24 mg/dl respectively. After three months of treatment the mean decrease was 62 +/- 31 mg/dl in total cholesterol (p < 0.001), 31 +/- 57 mg/dl in triglycerides (p < 0.001), 51 +/- 27 mg/dl in LDL-C (p < 0.001) and 4 +/- 8 mg/dl in HDL-C (p < 0.001). The LDL-C level was reduced by 37.6% in these patients, from 135 +/- 24 mg/dl to 84 = 27 mg/dl (p < 0.001) with 10 mg of atorvastatin daily. It was possible to achieve target LDL-C of less than 100 mg/dl in 75.5% (n=58) in subjects without CHD (n=77) and less than 70 mg/dl in 75% (n=3) of those patients with CHD (n=4). The present study showed that in patients with type 2 diabetes mellitus, 10 mg of atorvastatin daily was safe, well tolerated, and effective in reducing LDL-C to target levels.

Authors+Show Affiliations

Department of Endocrinology, Sri Venkateswara Institute of Medical Sciences, Tirupati 517507.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

20469785

Citation

Pola, Pramod, et al. "Efficacy of Low Dose Atorvastatin in Diabetic Dyslipidaemia." Journal of the Indian Medical Association, vol. 107, no. 11, 2009, pp. 807-9.
Pola P, Kumar R, Reddy AP, et al. Efficacy of low dose atorvastatin in diabetic dyslipidaemia. J Indian Med Assoc. 2009;107(11):807-9.
Pola, P., Kumar, R., Reddy, A. P., Rajagopal, G., Harinarayan, C. V., Suresh, V., Suchitra, M. M., & Sachan, A. (2009). Efficacy of low dose atorvastatin in diabetic dyslipidaemia. Journal of the Indian Medical Association, 107(11), 807-9.
Pola P, et al. Efficacy of Low Dose Atorvastatin in Diabetic Dyslipidaemia. J Indian Med Assoc. 2009;107(11):807-9. PubMed PMID: 20469785.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of low dose atorvastatin in diabetic dyslipidaemia. AU - Pola,Pramod, AU - Kumar,Ravishankar, AU - Reddy,Amaresh P, AU - Rajagopal,G, AU - Harinarayan,C V, AU - Suresh,V, AU - Suchitra,M M, AU - Sachan,Alok, PY - 2010/5/18/entrez PY - 2010/5/18/pubmed PY - 2010/7/23/medline SP - 807 EP - 9 JF - Journal of the Indian Medical Association JO - J Indian Med Assoc VL - 107 IS - 11 N2 - Coronary heart disease (CHD), the commonest cause of morbidity and mortality in patients with type 2 diabetes, requires multipronged approach for management, including especially treating dyslipidaemia with statins. We conducted this study to demonstrate that low dose (10 mg) atorvastatin is effective in reducing LDL cholesterol (LDL-C) to the target levels in patients from Indian subcontinent. Eighty-one subjects with type 2 diabetes mellitus and dyslipidaemia (LDL-C >100 mg/dl in those without coronary artery disease, n=77; LDL-C >70 mg/dl in those with coronary artery disease, n=4) were included. All patients were initiated on 10 mg atorvastatin daily. Serum lipid profile was repeated after 3 months. The mean body mass index among men and women were 25.0 +/- 4 and 26.7 +/- 3.6 kg/m2 respectively. Pretreatment mean HbA(1c) was 7.9 +/- 1.8 % and total cholesterol, triglycerides and HDL cholestrol (HDL-C) and LDL-C was 214 +/- 27 mg/dl, 164 +/- 63 mg/dl, 46 +/- 6 mg/dl and 135 +/- 24 mg/dl respectively. After three months of treatment the mean decrease was 62 +/- 31 mg/dl in total cholesterol (p < 0.001), 31 +/- 57 mg/dl in triglycerides (p < 0.001), 51 +/- 27 mg/dl in LDL-C (p < 0.001) and 4 +/- 8 mg/dl in HDL-C (p < 0.001). The LDL-C level was reduced by 37.6% in these patients, from 135 +/- 24 mg/dl to 84 = 27 mg/dl (p < 0.001) with 10 mg of atorvastatin daily. It was possible to achieve target LDL-C of less than 100 mg/dl in 75.5% (n=58) in subjects without CHD (n=77) and less than 70 mg/dl in 75% (n=3) of those patients with CHD (n=4). The present study showed that in patients with type 2 diabetes mellitus, 10 mg of atorvastatin daily was safe, well tolerated, and effective in reducing LDL-C to target levels. SN - 0019-5847 UR - https://www.unboundmedicine.com/medline/citation/20469785/Efficacy_of_low_dose_atorvastatin_in_diabetic_dyslipidaemia_ L2 - https://medlineplus.gov/cholesterolmedicines.html DB - PRIME DP - Unbound Medicine ER -